Classical Hodgkin Lymphoma
A RANDOMISED PHASE III TRIAL TO
ASSESS RESPONSE ADAPTED
THERAPY USING FDG-PET IMAGING
IN PATIENTS WITH NEWLY
DIAGNOSED, ADVANCED HODGKIN
LYMPHOMA
A randomised phase III trial to determine the role of FDG-P imaging in clinical stages IA/IIA Hodgkins disease.
To evaluate the efficacy and toxicity of VEPEMB in a phase II study in older patients with Hodgkins Lymphoma (HL). A number of older patients with HL fail to enter clinical trials as they are "not fit" for multiple drug chemotherapy. This study will aim to include all pathologically eligible patients in participating centres in order to provide a clearer overall clinical picture of this disease, whether or not they undergo protocol chemotherapy.